Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.

Authors:
Flieswasser T; Van den Eynde A; Freire Boullosa L; Melis J; Hermans C and 7 more

Journal:
Oncoimmunology

Publication Year: 2023

DOI:
10.1080/2162402X.2023.2192100

PMCID:
PMC10038060

PMID:
36970072

View on PubMed View on PMC View Publisher

Journal Information

Full Title: Oncoimmunology

Abbreviation: Oncoimmunology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal

View All Papers from This Journal

Transparency Score

2/6

33.3% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"Disclosure statement No potential conflict of interest was reported by the authors."

Funding Disclosure

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025

Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer.

Journal Information

Publication Details

Related Papers from Same Journal

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor ac…

An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherap…

Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.

Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8<sup>+</sup>T cell func…

Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor …

Transparency Score

Transparency Indicators

Core Indicators

Additional Indicators

Assessment Info